{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:10:23Z","timestamp":1778591423080,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.110992","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:49:52Z","timestamp":1770410992000},"page":"110992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Statin use and outcomes in advanced prostate cancer:Secondary analysis of the SPARTAN trial"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-8048","authenticated-orcid":false,"given":"Ahmad","family":"Mousa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Chavarriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Lajkosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda Z.","family":"Penn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najia","family":"Khurram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.110992_bib0001","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ncpuro1295","article-title":"Does statin use affect the risk of developing prostate cancer?","volume":"6","author":"Platz","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.urolonc.2026.110992_bib0002","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1940-6207.CAPR-17-0396","article-title":"Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study","volume":"11","author":"Mondul","year":"2018","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.urolonc.2026.110992_bib0003","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1002\/cncr.25308","article-title":"Statin medication use and the risk of biochemical recurrence after radical prostatectomy","volume":"116","author":"Hamilton","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.110992_bib0004","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-19-2853","article-title":"Statin use is associated with lower risk of PTEN-null and lethal prostate cancer","volume":"26","author":"Allott","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.110992_bib0005","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1111\/j.1464-410X.2012.11527.x","article-title":"Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies","volume":"111","author":"Scosyrev","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.110992_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.2013.49.4757","article-title":"Use of statins and the risk of death in patients with prostate cancer","volume":"32","author":"Yu","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.110992_bib0007","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2015.0829","article-title":"Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer","volume":"1","author":"Harshman","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.110992_bib0008","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1158\/1078-0432.CCR-21-0480","article-title":"Adjuvant low-dose statin use after radical prostatectomy: The PRO-STAT randomized clinical trial","volume":"27","author":"Jeong","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.110992_bib0009","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2018.06.037","article-title":"Atorvastatin versus placebo for prostate cancer before radical prostatectomy\u2014a randomized, double-blind, placebo-controlled clinical trial","volume":"74","author":"Murtola","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.110992_bib0010","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1055-9965.EPI-07-0599","article-title":"Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study","volume":"16","author":"Murtola","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2026.110992_bib0011","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.euf.2016.05.004","article-title":"Statin use and prostate cancer survival in the Finnish randomized study of screening for prostate cancer","volume":"3","author":"Murtola","year":"2017","journal-title":"Euro Urol Focus"},{"key":"10.1016\/j.urolonc.2026.110992_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.71.8981","article-title":"Postdiagnosis statin use and mortality in Danish patients with prostate cancer","volume":"35","author":"Larsen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.110992_bib0013","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Emberson","year":"2012","journal-title":"Plos One"},{"key":"10.1016\/j.urolonc.2026.110992_bib0014","doi-asserted-by":"crossref","first-page":"19861","DOI":"10.18632\/oncotarget.24888","article-title":"Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study","volume":"9","author":"Gordon","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2026.110992_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161959","article-title":"Influence of statins on survival outcome in patients with metastatic castration resistant prostate cancer treated with abiraterone acetate","volume":"11","author":"Boegemann","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.urolonc.2026.110992_bib0016","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/pros.23390","article-title":"The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer","volume":"77","author":"Harshman","year":"2017","journal-title":"Prostate"},{"issue":"15","key":"10.1016\/j.urolonc.2026.110992_bib0017","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.urolonc.2026.110992_bib0018","first-page":"2091","article-title":"Overall survival with apalutamide in nmCRPC","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.urolonc.2026.110992_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42676","article-title":"Statin use and survival among men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis","volume":"5","author":"Jayalath","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.urolonc.2026.110992_bib0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.eururo.2020.12.031","article-title":"The association between statin use and outcomes in patients initiating androgen deprivation therapy","volume":"79","author":"Hamilton","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.110992_bib0021","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2026.110992_bib0023","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-16-2245","article-title":"Association of tissue abiraterone levels and SLCO genotype with intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer","volume":"23","author":"Mostaghel","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.urolonc.2026.110992_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.08.023","article-title":"Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial","volume":"43","author":"Chavarriaga","year":"2025","journal-title":"Urol Oncol: Sem Original Investig"},{"issue":"11","key":"10.1016\/j.urolonc.2026.110992_bib0025","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1210\/endo.142.11.8467","article-title":"Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state","volume":"142","author":"Murillo","year":"2001","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.urolonc.2026.110992_bib0026","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccr.2009.07.016","article-title":"FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt","volume":"16","author":"Pei","year":"2009","journal-title":"Cancer cell"},{"issue":"8","key":"10.1016\/j.urolonc.2026.110992_bib0027","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1210\/en.2004-0311","article-title":"Identification and validation of novel androgen-regulated genes in prostate cancer","volume":"145","author":"Velasco","year":"2004","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.urolonc.2026.110992_bib0028","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000155845.44729.ba","article-title":"Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer","volume":"173","author":"Febbo","year":"2005","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.110992_bib0029","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/08977190412331279908","article-title":"Androgen receptor cross-talk with cell signalling pathways","volume":"22","author":"Culig","year":"2004","journal-title":"Growth Factors"},{"key":"10.1016\/j.urolonc.2026.110992_bib0030","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40262-020-00882-2","article-title":"Pharmacokinetic drug\u2013drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer","volume":"59","author":"Duran","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.urolonc.2026.110992_bib0032","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/COC.0000000000001012","article-title":"Association between statin exposure and incidence and prognosis of prostate cancer: a meta-analysis based on observational studies","volume":"46","author":"Cao","year":"2023","journal-title":"Am J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:22:24Z","timestamp":1778588544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1078143926000025"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.110992","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin use and outcomes in advanced prostate cancer:Secondary analysis of the SPARTAN trial","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.110992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110992"}}